Trial Profile
A Phase 2 Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Odetiglucan (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Biothera
- 14 Feb 2012 Actual patients number is 18 as reported by ClinicalTrials.gov.
- 14 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 14 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.